Business Wire

Navan Selected by Opella to Streamline Global Travel and Expense

15.4.2026 09:01:00 CEST | Business Wire | Press Release

Share

Navan (NASDAQ: NAVN), the global AI-powered business travel and expense management platform, today announced it has been selected by Opella to manage its global travel and expense programme.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415188706/en/

Self-care company aims to simplify employee T&E experience and targets cost savings with AI-powered platform

“Navan provides our teams with an easy-to-use tool that removes the complexity from business travel and expense, improving our employee experience and giving us the real-time visibility required to effectively manage costs,” said Vincent Cotard, VP Global Head Real Estate and Workplace Experience at Opella. "Our employees will now have the easiest way to book travel and manage their expenses as we look to automate processes across the business.”

Following Opella’s carve-out from Sanofi, the self-care company sought an AI-powered partner to provide employees with an easy-to-use travel platform and to optimize spending. Initial conversations began about Navan's travel product and Opella extended the partnership to also include Navan’s expense product, giving them end-to-end control and visibility of their entire travel and expense outlay.

Anticipated benefits from the partnership with Navan include:

  • Cost savings: Targeting savings of up to 20% on annual travel spend through access to competitive pricing and reduced fees.
  • High adoption: Aiming for 95% platform adoption and a 96% traveller satisfaction score.
  • Operational efficiency: Saving an estimated 15 minutes per booking through AI-assisted capabilities and improved self-serve access across both web and mobile applications.

“We’re thrilled to partner with Opella to modernise their global travel and expense programme,” said Zahir Abdelouhab, SVP, EMEA, Navan. “By addressing issues with their existing inventory, we are confident that Opella will achieve the adoption rates and savings necessary to meet their goals.”

Opella joins a growing list of enterprise organizations that have recently switched to Navan, including industry leaders from across France, including Alcatel-Lucent, Lafarge, and Expleo.

About Opella

Opella is the self-care challenger with the purest and third-largest portfolio in the Over-The-Counter (OTC) & Vitamins, Minerals & Supplements (VMS) market globally. Our mission is to bring health into people’s hands by making self-care as simple as it should be. For half a billion consumers worldwide – and counting. At the core of this mission is our 100 loved brands, our 11,000-strong global team, our 13 best-in-class manufacturing sites and 4 specialized science and innovation development centers. Headquartered in France, Opella is the proud maker of many of the world’s most loved brands, including Allegra, Buscopan, Doliprane, Dulcolax, Enterogermina, Essentiale and Mucosolvan. B Corp certified globally, we are active players in the journey towards healthier people and planet.

About Navan

Navan (NASDAQ: NAVN) is the global AI-powered business travel and expense platform that makes travel easy for frequent travelers. From finding flights and hotels, to automating expense reconciliation, with 24/7 support along the way, Navan delivers an intuitive experience travelers love and finance teams rely on. See how Navan customers benefit and learn more at navan.com.

Forward Looking Statements

All statements in this press release other than statements of historical fact could be deemed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are often identified by words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “will,” or similar expressions. Such statements are subject to risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. These risks and other factors include the risks described under the caption “Risk Factors” in Navan’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on April 2, 2026, as they may be updated by Navan’s subsequent filings with the SEC. Except as required by law, Navan undertakes no obligation, and does not intend, to update these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260415188706/en/

Contacts

Navan Press press@navan.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SOLUM Receives Two Red Dot Product Design Awards for Shelf-Edge and In-Store Communication Solutions15.4.2026 10:20:00 CEST | Press Release

SOLUM (KOSPI: 248070) has received the Red Dot Award: Product Design for Newton Core+ and Newton E-Paper 32”, with both products recognised for addressing core retail requirements across function, design quality, ease of use, and responsibility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415714608/en/ Red Dot Product Design Awards 2026 highlight Newton Core+ and Newton E-Paper 32” (Image: SOLUM) As retailers place greater emphasis on solutions that support store presentation, operational usability, and long-term reliability, the awards highlight two products developed around those priorities. Newton Core+ and Newton E-Paper 32” reflect a retail technology approach shaped by the practical demands of the store environment, where visual consistency, day-to-day usability, and dependable performance all matter. Newton Core+: Premium Shelf-Edge Design Must Also Withstand Daily Retail Use For Newton Core+, the recognition hi

SOLUM Receives Two Red Dot Product Design Awards for Shelf-Edge and In-Store Communication Solutions15.4.2026 10:20:00 CEST | Press Release

SOLUM (KOSPI: 248070) has received the Red Dot Award: Product Design for Newton Core+ and Newton E-Paper 32”, with both products recognised for addressing core retail requirements across function, design quality, ease of use, and responsibility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415714608/en/ Red Dot Product Design Awards 2026 highlight Newton Core+ and Newton E-Paper 32” (Image: SOLUM) As retailers place greater emphasis on solutions that support store presentation, operational usability, and long-term reliability, the awards highlight two products developed around those priorities. Newton Core+ and Newton E-Paper 32” reflect a retail technology approach shaped by the practical demands of the store environment, where visual consistency, day-to-day usability, and dependable performance all matter. Newton Core+: Premium Shelf-Edge Design Must Also Withstand Daily Retail Use For Newton Core+, the recognition hi

Meiji Seika Pharma’s Nacubactam to Be Featured in 10 Presentations at ESCMID Global 2026 — Including Phase III Integral-2 Results15.4.2026 08:00:00 CEST | Press Release

Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that at ESCMID Global 2026, to be held from 17 to 21 April 2026, it will present a total of ten studies on its novel β-lactamase inhibitor nacubactam (development code: OP0595), for which a manufacturing and marketing authorisation application is under review in Japan. The presentations include results from Integral-2, an international, multicentre Phase III clinical trial in patients with infections due to carbapenem-resistant Enterobacterales (CRE). Currently, carbapenem-resistant bacteria pose a global threat because carbapenems are considered last-resort agents for severe infections. The development and approval of effective agents against multidrug-resistant Gram-negative bacteria, including CRE, are urgently needed (WHO Bacterial Priority Pathogens List, 2024). In December 2025, Meiji Seika Pharma submitted an application for manufacturing and marketing

Meiji Seika Pharma’s Nacubactam to Be Featured in 10 Presentations at ESCMID Global 2026 — Including Phase III Integral-2 Results15.4.2026 08:00:00 CEST | Press Release

Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that at ESCMID Global 2026, to be held from 17 to 21 April 2026, it will present a total of ten studies on its novel β-lactamase inhibitor nacubactam (development code: OP0595), for which a manufacturing and marketing authorisation application is under review in Japan. The presentations include results from Integral-2, an international, multicentre Phase III clinical trial in patients with infections due to carbapenem-resistant Enterobacterales (CRE). Currently, carbapenem-resistant bacteria pose a global threat because carbapenems are considered last-resort agents for severe infections. The development and approval of effective agents against multidrug-resistant Gram-negative bacteria, including CRE, are urgently needed (WHO Bacterial Priority Pathogens List, 2024). In December 2025, Meiji Seika Pharma submitted an application for manufacturing and marketing

Invivoscribe Announces the PrepQuant ™ System, an Integrated Sample Preparation Platform that Standardizes and Streamlines Pre-Analytical Workflows15.4.2026 07:05:00 CEST | Press Release

Invivoscribe®, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced the launch of the PrepQuant™ System, a novel sample preparation platform that integrates nucleic acid extraction, concentration, and quantification with a single automated instrument. This innovative system is designed to standardize sample preparation and simplify pre-analytical workflows to reduce costs and eliminate a primary source of inconsistency in molecular testing. Developed in collaboration with Hitachi High-Tech Corporation, the PrepQuant System combines Invivoscribe’s expertise in developing standardized molecular assays, providing global clinical testing services, along with Hitachi High-Tech’s proven technological and manufacturing capabilities. Hitachi High-Tech has an extensive global installed base of life science and clinical diagnostic instruments. The PrepQuant System is assay agnostic, generating highly concentrated genomic DNA and cell free DNA (c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye